8-K current report · filed Jul 21, 2026

Krystal Biotech, Inc. (KRYS) 8-K Current Report: July 21, 2026

Item 8.01KRYS overview

Short answer

Krystal Biotech, Inc. (KRYS) filed an 8-K current report with the SEC on July 21, 2026 reporting Item 8.01 (Other Events). KB801 patient achieved complete closure of a persistent corneal epithelial defect, supporting patentability claims.

Krystal Biotech, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • KB801 patient achieved complete closure of a persistent corneal epithelial defect, supporting patentability claims
  • Observation came from a discontinued clinical study advanced toward a pivotal trial
  • No safety concerns or serious adverse events observed in treated study patients
  • Single-patient result is not clinical-trial efficacy evidence, limiting investment conclusions
  • Pivotal-trial results remain the key upcoming catalyst for KB801 valuation

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Krystal Biotech, Inc. 8-K filings

Get the next KRYS 8-K as it lands

Follow KRYS for push alerts, or ask the research agent what this filing means.